BIOMAT Database Logo BIOMAT Database Logo

Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. 2003

Hua Zhao, and H Barton Grossman, and Margaret R Spitz, and Seth P Lerner, and Kerang Zhang, and Xifeng Wu
Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

OBJECTIVE Because insulin-like growth factors (IGFs) and their binding proteins have been implicated in the development of prostate, breast, colon and lung cancer, we examined the role of IGF-1 and IGF binding protein-3 levels in bladder cancer risk. METHODS We used an enzyme-linked immunosorbent assay to compare plasma levels of IGF-1 and IGF binding protein-3 in 154 patients with bladder cancer and 154 controls from an ongoing case-control study. RESULTS Mean IGF-1 was significantly higher in cases than in controls (175.8 versus 153.2 ng./ml., p <0.01). Mean IGF binding protein-3 was significantly lower in cases than in controls (2,632.9 versus 3,056.6 ng./ml., p <0.01). The highest quartile plasma levels of IGF-1 were associated with an increased risk of bladder cancer (OR 3.10, 95% CI 1.43 to 6.70) and the highest quartile plasma levels of IGF binding protein-3 were associated with a reduced risk of bladder cancer (OR 0.38, 95% CI 0.19 to 0.78). The effects were more striking when IGF-1 and IGF binding protein-3 levels were analyzed together. In addition, a higher molar ratio of IGF-1-to-IGF binding protein-3 was associated with an increased risk of bladder cancer (OR 4.30, 95% CI 1.99 to 9.28). Dose-response relationships were evident when subjects were categorized into quartiles by the values of IGF-1, IGF binding protein-3 and the molar ratio in controls. CONCLUSIONS To our knowledge this is the first study to suggest that patients with bladder cancer have higher plasma levels of IGF-1 and lower levels of IGF binding protein-3 than controls. Thus, measuring plasma IGF-1 and IGF binding protein-3 may be useful for assessing bladder cancer risk.

UI MeSH Term Description Entries
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D018972 Insulin-Like Growth Factor Binding Protein 3 One of the six homologous soluble proteins that bind insulin-like growth factors (SOMATOMEDINS) and modulate their mitogenic and metabolic actions at the cellular level. IGF-Binding Protein 3,IGFBP-3,IGF Binding Protein 3,Protein 3, IGF-Binding

Related Publications

Hua Zhao, and H Barton Grossman, and Margaret R Spitz, and Seth P Lerner, and Kerang Zhang, and Xifeng Wu
Associations of genetically predicted circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with bladder cancer risk.
November 2021, Molecular carcinogenesis,
Hua Zhao, and H Barton Grossman, and Margaret R Spitz, and Seth P Lerner, and Kerang Zhang, and Xifeng Wu
Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk.
May 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Hua Zhao, and H Barton Grossman, and Margaret R Spitz, and Seth P Lerner, and Kerang Zhang, and Xifeng Wu
Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia.
September 2010, Journal of gynecologic oncology,
Hua Zhao, and H Barton Grossman, and Margaret R Spitz, and Seth P Lerner, and Kerang Zhang, and Xifeng Wu
Vertex balding, plasma insulin-like growth factor 1, and insulin-like growth factor binding protein 3.
June 2000, Journal of the American Academy of Dermatology,
Hua Zhao, and H Barton Grossman, and Margaret R Spitz, and Seth P Lerner, and Kerang Zhang, and Xifeng Wu
Somatomedin-1 binding protein-3: insulin-like growth factor-1 binding protein-3, insulin-like growth factor-1 carrier protein.
January 2003, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Hua Zhao, and H Barton Grossman, and Margaret R Spitz, and Seth P Lerner, and Kerang Zhang, and Xifeng Wu
Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden.
May 2002, Gut,
Hua Zhao, and H Barton Grossman, and Margaret R Spitz, and Seth P Lerner, and Kerang Zhang, and Xifeng Wu
Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer.
December 2013, Breast (Edinburgh, Scotland),
Hua Zhao, and H Barton Grossman, and Margaret R Spitz, and Seth P Lerner, and Kerang Zhang, and Xifeng Wu
Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels with risk of malignant melanoma.
September 2011, Cancer causes & control : CCC,
Hua Zhao, and H Barton Grossman, and Margaret R Spitz, and Seth P Lerner, and Kerang Zhang, and Xifeng Wu
Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors.
June 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Hua Zhao, and H Barton Grossman, and Margaret R Spitz, and Seth P Lerner, and Kerang Zhang, and Xifeng Wu
Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk.
November 2003, British journal of cancer,
Copied contents to your clipboard!